Price
$1.18
Decreased by -1.67%
Dollar volume (20D)
4.35 M
ADR%
9.43
Earnings report date
May 12, 2025
Shares float
156.35 M
Shares short
32.81 M [20.99%]
Shares outstanding
218.70 M
Market cap
371.80 M
Beta
0.99
Price/earnings
N/A
20D range
1.09 1.78
50D range
1.09 2.32
200D range
1.09 3.78

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma.

In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia.

The company has license and collaboration agreements with Pfizer Inc., Servier, CellectisS. A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3.

The company was incorporated in 2017 and is headquartered in South San Francisco, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Mar 12, 25 -0.28
Increased by +34.88%
-0.32
Increased by +13.42%
Nov 7, 24 -0.32
Increased by +13.51%
-0.33
Increased by +3.03%
Aug 7, 24 -0.35
Increased by +33.96%
-0.35
May 13, 24 -0.38
Increased by +44.12%
-0.41
Increased by +7.32%
Mar 14, 24 -0.43
Increased by +34.85%
-0.45
Increased by +4.44%
Nov 2, 23 -0.37
Increased by +36.21%
-0.52
Increased by +28.85%
Aug 2, 23 -0.53
Decreased by -1.92%
-0.59
Increased by +10.17%
May 3, 23 -0.68
Decreased by -21.43%
-0.62
Decreased by -9.68%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 0.00
Decreased by -100.00%
-59.94 M
Increased by +30.12%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by -100.00%
-66.29 M
Decreased by -8.12%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by -100.00%
-66.36 M
Increased by +14.91%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 22.00 K
Decreased by -57.69%
-65.00 M
Increased by +33.90%
Decreased by -295.45 K%
Decreased by -56.23%
Dec 31, 23 21.00 K
Decreased by -55.32%
-85.78 M
Increased by +8.08%
Decreased by -408.47 K%
Decreased by -105.72%
Sep 30, 23 43.00 K
Decreased by -12.24%
-61.31 M
Increased by +26.26%
Decreased by -142.59 K%
Increased by +15.97%
Jun 30, 23 44.00 K
Decreased by -48.84%
-77.99 M
Decreased by -4.72%
Decreased by -177.25 K%
Decreased by -104.69%
Mar 31, 23 52.00 K
Decreased by -14.75%
-98.34 M
Decreased by -23.37%
Decreased by -189.11 K%
Decreased by -44.73%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY